IBRX, NasdaqGS

ImmunityBio, Inc. (IBRX)

Price (as of September 30)

4.94USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

ADGI

Adagio Therapeutics, Inc.

-0.18

AURA

Aura Biosciences, Inc.

-0.17

DSGN

Design Therapeutics, Inc.

-0.11

BTTX

Better Therapeutics, Inc.

-0.11

ADTX

Aditxt, Inc.

-0.1

CARA

Cara Therapeutics, Inc.

-0.09

BWV

Blue Water Vaccines, Inc.

-0.09

BCTX

BriaCell Therapeutics Corp.

-0.08

ARQT

Arcutis Biotherapeutics, Inc.

-0.08

DNA

Ginkgo Bioworks Holdings, Inc.

-0.08

Show more

Highest within Industry

Symbol Correlation

CGTX

Cognition Therapeutics, Inc.

0.16

DBTX

Decibel Therapeutics, Inc.

0.12

ALLR

Allarity Therapeutics, Inc.

0.11

BPTS

Biophytis S.A.

0.1

RXRX

Recursion Pharmaceuticals, Inc.

0.09

DTIL

Precision BioSciences, Inc.

0.08

ELYM

Eliem Therapeutics, Inc.

0.08

BNOX

Bionomics Limited

0.08

ANGN

Angion Biomedica Corp.

0.08

ADAG

Adagene Inc.

0.08

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.